Skip to main content

Advertisement

SpringerLink
Log in

Topical Brimonidine 0.2%/Timolol 0.5% Ophthalmic Solution

In Glaucoma and Ocular Hypertension

  • Adis Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

  • ▲ A fixed combination of brimonidine (a highly selective α2-adrenergic agonist) and timolol (a non-selective α-blocker) [brimonidine 0.2%/timolol 0.5% ophthalmic solution; brimonidine/timolol] is available for the topical treatment of glaucoma and ocular hypertension (OH).

  • ▲ Brimonidine and timolol decrease elevated intraocular pressure (IOP) by complementary mechanisms of action and have an additive effect when coadministered to healthy volunteers and patients with glaucoma or OH.

  • ▲ When assessed over a 3-or 12-month period in large, well designed clinical studies, brimonidine/timolol instilled twice daily (one drop in each eye) was superior to monotherapy with the individual components instilled two (brimonidine) or three (timolol) times daily, and noninferior to concomitant therapy with the individual components instilled twice daily, in lowering raised IOP in patients with glaucoma or OH.

  • ▲ In small, randomised, comparative studies of 1 or 3 months’ duration, the IOP-lowering effect of brimonidine/timolol twice daily was similar or superior to that of fixed combination dorzolamide 2%/timolol 0.5% ophthalmic solution (dorzolamide/timolol) twice daily (preliminary data).

  • ▲ Brimonidine/timolol is generally well tolerated with a predictable local and systemic adverse event profile based on that of the individual components used alone and concomitantly. No unexpected or serious adverse events associated with the fixed combination were reported in key clinical trials.

  • ▲ Brimonidine/timolol may be advantageous over dorzolamide/timolol with respect to ocular tolera-bility and comfort (preliminary data).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician 1999; 60: 99–108

    PubMed  CAS  Google Scholar 

  2. The Merck Manual. Section 8. Ophthalmological Disorders. Chapter 100. Glaucoma [online]. Available from URL: http://www.merck.com/mrkshared/mmanual/home.jsp [Accessed 2006 Aug 10]

  3. Rouland J-F, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension. Implications for patient management: a review. Drugs Aging 2005; 22(4): 315–21

    Article  PubMed  Google Scholar 

  4. Goldberg LD. Clinical guidelines for the treatment of glaucoma. Manag Care 2002 Nov; 11 (11 Suppl.): 16–24

    PubMed  Google Scholar 

  5. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol 2004; 15: 119–26

    Article  PubMed  Google Scholar 

  6. The Royal College of Ophthalmologists. Guidelines for the management of open angle glaucoma and ocular hypertension [online]. Available from URL: http://www.rcophth.ac.uk [Accessed 2006 Aug 10]

  7. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004; 15(2): 132–5

    Article  PubMed  Google Scholar 

  8. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 2005; 22(1): 1–21

    Article  PubMed  CAS  Google Scholar 

  9. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001 Apr; 23(4): 604–19

    Article  PubMed  CAS  Google Scholar 

  10. Stewart WC. Combination therapy: is the whole greater? Rev Ophthalmol 2005; 12(6) [online]. Available from URL: http://www.revophth.com [Accessed 2006 Sep 28]

    Google Scholar 

  11. Allergan Ltd. Combigan eye drops, solution. Summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2006 Aug 10]

  12. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995 Dec; 113(12): 1514–7

    Article  PubMed  CAS  Google Scholar 

  13. Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res 2004 Mar; 78(3): 639–51

    Article  PubMed  CAS  Google Scholar 

  14. Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol 2001 Apr; 119(4): 492–5

    Article  PubMed  CAS  Google Scholar 

  15. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997 Jan; 104(1): 131–6

    PubMed  CAS  Google Scholar 

  16. Carlsson AM, Chauhan BC, Lee A, et al. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol 1999; 128: 697–701

    Article  PubMed  CAS  Google Scholar 

  17. Lachkar Y, Migdal C, Dhanjil S. Effect of brimonidine tartrate on ocular hemodynamic measurements. Arch Ophthalmol 1998 Dec; 116: 1591–4

    PubMed  CAS  Google Scholar 

  18. Costagliola C, Parmeggiani F, Ciancaglini M, et al. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Ophthalmologica 2003 Jan 28; 217(1): 39–44

    Article  PubMed  CAS  Google Scholar 

  19. Liu CJ, Ko YC, Cheng CY, et al. Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma. Br J Ophthalmol 2002 Nov; 86(11): 1236–9

    Article  PubMed  Google Scholar 

  20. Fuchsjager-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 2005 Oct; 89(10): 1293–7

    Article  PubMed  CAS  Google Scholar 

  21. Arend O, Harris A, Wolter P, et al. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients. Acta Ophthalmol Scand 2003 Oct; 81(5): 474–9

    Article  PubMed  CAS  Google Scholar 

  22. Galassi F, Sodi A, Renieri G, et al. Effects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucoma. Ophthalmo-logica 2002 Mar; 216(2): 123–8

    Article  CAS  Google Scholar 

  23. Adkins JC, Balfour JA. Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998 Mar; 12: 225–41

    Article  PubMed  CAS  Google Scholar 

  24. Stewart WC, Stewart JA, Jackson AL. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. Acta Ophthalmol Scand 2002 Jun; 80(3): 277–81

    Article  PubMed  CAS  Google Scholar 

  25. Korte J-M, Kailaa T, Matti Saari K. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefe’s Arch Clin Exp Ophthalmol 2002; 240: 430–5

    Article  CAS  Google Scholar 

  26. Heel RC, Brogden RN, Speight TM, et al. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs 1979; 17: 38–55

    Article  PubMed  CAS  Google Scholar 

  27. Data on file, Allergan I, 2006

  28. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2006; 124: 1–9

    Article  Google Scholar 

  29. Goni FJ, Brimonidine/Timolol Fixed Combination Study Group. 12-Week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005 Sep 31; 15(No. 5): 581–90

    PubMed  CAS  Google Scholar 

  30. Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005 Aug; 21(4): 337–48

    Article  PubMed  CAS  Google Scholar 

  31. Buchholz P, Poulsen PB, Walt JG. A cost-minimization analysis of Combigan (brimonidine/timolol, fixed combination) in the treatment of primary open angle glaucoma in Europe [abstract plus poster presented at the 6th International Symposium on Ocular Pharmacology and Therapeutics; 2006 Mar 30-Apr 2; Berlin] [online]. Available from URL: http://www.kenes.com/isopt2006/ [Accessed 2006 Sep]

  32. Nixon DR. Evaluation of the safety and efficacy of brimonidine tartrate-timolol maleate ophthalmic solution (Combigan®) and dorzolamide hydrochloride-timolol maleate ophthalmic solution (Cosopt®) in patients with open-angle glaucoma or ocular hypertension [abstract no. E-453-B188 plus poster presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2006 Apr 30-May 4; Ft Lauderdale (FL)]. Invest Ophthalmol Vis Sci 2006; 47 [online]. Available from URL: http://www.iovs.org[Accessed 2006 Sep]

  33. Arcieri ES, Pereira ACA, Andreo EGV, et al. Fixed combination brimonidine-timolol (Combigan®) versus fixed combination dorzolamide-timolol (Cosopt®) each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension [abstract no. E-434-B169]. Invest Ophthalmol Vis Sci 2006; 47 [online]. Available from URL: http://www.iovs.org [Accessed 2006 Sep]

  34. Crichton ACS. Timolol/brimonidine combination therapy in glaucoma management. Clin Surg Ophthalmol 2005; 23(10): 356–9

    Google Scholar 

  35. Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003; 110: 615–24

    Article  PubMed  Google Scholar 

  36. Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004; 13: 149–57

    Article  PubMed  Google Scholar 

  37. Ventura MP, Saheb NE, Solari HP, et al. Cost considerations of the new fixed combinations for glaucoma medical therapy. J Clin Pharm Ther 2005; 30(3): 251–4

    Article  PubMed  CAS  Google Scholar 

  38. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996 Nov; 41(Suppl. 1): 27–37

    Article  Google Scholar 

  39. Motolko MA, Crichton A. A comparison of allergy rates in glaucoma patients receiving brimonidine monotherapy versus fixed combination brimonidine/timolol. Presented at the American Glaucoma Society Annual Meeting; 2006 Mar 2–5; Charleston (SC)

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health, Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    James E. Frampton

  2. Editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E. Topical Brimonidine 0.2%/Timolol 0.5% Ophthalmic Solution. Drugs Aging 23, 753–761 (2006). https://doi.org/10.2165/00002512-200623090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200623090-00005

Keywords

Search

Navigation